The report provides a detailed analysis essential for establishing a Belzutifan production plant. It encompasses all critical aspects necessary for Belzutifan production, including the cost of Belzutifan production, Belzutifan plant cost, Belzutifan production costs, and the overall Belzutifan production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Belzutifan production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Belzutifan is a targeted pharmaceutical compound that is mainly used in the treatment of specific cancer conditions. It is primarily prescribed for patients with von Hippel–Lindau (VHL) disease, where it helps manage tumours linked to this genetic disorder. The drug works by blocking certain proteins involved in tumour growth, which helps slow down or stop the development of cancer cells. It is also utilised for managing VHL-associated renal cell carcinoma, central nervous system hemangioblastomas, and pancreatic neuroendocrine tumours. It is also being studied in clinical trials for other cancers where HIF-2α is a known factor. In addition to oncology care, it is often used to support long-term disease management by reducing the need for repeated surgeries in some patients.
The demand for Belzutifan is primarily led by its application as an important medicine in targeted cancer therapy, which boosts its market growth. Its application in the treatment of certain types of tumours associated with von Hippel-Lindau (VHL) disease, which fuels its demand in the medical sector. Its usage in the treatment of kidney cancer, as well as tumours affecting the pancreas and central nervous system associated with VHL disease, also drives its demand in the pharmaceutical industry. Its demand for inhibiting hypoxia-inducible factor-2 alpha (HIF-2α), which plays a major role in the growth and survival of cancer cells under low oxygen conditions, also promotes its market expansion.
Its involvement in research to examine its potential use in other cancers due to its specificity and relatively favourable safety profile also contributes to its market demand. The growing focus on precision medicine and the increasing incidence of VHL-related and HIF-2α-expressing tumours significantly boost its market demand. Additionally, ongoing research into broader oncology applications and combination therapies further supports market interest. Industrial Belzutifan procurement is influenced by factors such as the complexity of peptide-based synthesis, availability and cost of starting materials, compliance with regulatory standards, and sustainability practices. Supplier reliability, patent coverage, and the need for specialised handling also play important roles in shaping procurement and distribution strategies for Belzutifan.
Raw Material for Belzutifan Production
According to the Belzutifan production plant project report, the major raw materials for Belzutifan production include 3,4-dihydrocoumarin, 3,5-difluorobenzonitrile, Selectfluor, and Perfluoro-1-butanesulfonyl fluoride.
Production Process of Belzutifan
The extensive Belzutifan production cost report consists of the following industrial production process:
- Production from 3,4-dihydrocoumarin: The production process of Belzutifan begins with 3,4-dihydrocoumarin, which is brominated under Lewis acid conditions to form a reactive intermediate. Then, this intermediate undergoes a lactone ring opening and a nucleophilic aromatic substitution with 3,5-difluorobenzonitrile, followed by acyl chloride formation and intramolecular Friedel–Crafts cyclisation to form an indanone core. Then, the methyl sulfone group is introduced using a copper-mediated reaction. The resulting ketone is protected as a ketal, then subjected to benzylic bromination and Kornblum oxidation to install a major ketone functionality. Further, asymmetric transfer hydrogenation using a ruthenium catalyst introduces the first chiral alcohol, and acid treatment removes the ketal, which gives a crystallised chiral intermediate. Then, this intermediate is fluorinated with Selectfluor, followed by another asymmetric transfer hydrogenation to achieve dynamic kinetic resolution. After isolating the desired fluorinated alcohol, the final stereocenter is set through deoxyfluorination using perfluoro-1-butanesulfonyl fluoride (PBSF), which produce high purity Belzutifan as the final product.
Belzutifan is a small-molecule inhibitor of hypoxia-inducible factor-2 alpha. It appears as a white to light brown powder, which is completely insoluble in water but demonstrates good solubility in acetonitrile, dimethoxyethane, and acetone. The molecular formula of the compound is C17H12F3NO4S, and its molecular weight is 383.34 g/mol. It is sparingly soluble in ethyl acetate and very slightly soluble in isopropanol and toluene. The compound is marketed under the brand name Welireg. Belzutifan is administered orally as tablets and is indicated for the treatment of von Hippel-Lindau disease-associated tumours. The compound is a known toxicant and may cause severe anaemia and hypoxia. It has the potential to cause embryo-fetal toxicity when administered to pregnant women and can make some hormonal contraceptives ineffective. Extended exposure to this medication may result in serious health problems, including anaemia, fatigue, headache, dizziness, increased creatinine levels, and nausea. Therefore, careful monitoring of haemoglobin levels and oxygen saturation is advised during treatment.
